Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 2147

1.

Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.

Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA.

Am J Geriatr Pharmacother. 2009 Oct;7(5):262-70. doi: 10.1016/j.amjopharm.2009.11.003.

PMID:
19948302
[PubMed - indexed for MEDLINE]
2.
3.

Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.

Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M.

J Manag Care Pharm. 2008 Mar;14(2):176-85.

PMID:
18331119
[PubMed - indexed for MEDLINE]
Free Article
4.

Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.

Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM.

Clin Ther. 2007 Jun;29(6):1203-13.

PMID:
17692734
[PubMed - indexed for MEDLINE]
5.

Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.

Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM.

Am J Manag Care. 2008 Jul;14(7):438-48.

PMID:
18611095
[PubMed - indexed for MEDLINE]
Free Article
6.

Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.

Dalal AA, Roberts MH, Petersen HV, Blanchette CM, Mapel DW.

Int J Chron Obstruct Pulmon Dis. 2010 Dec 31;6:13-22. doi: 10.2147/COPD.S15455.

PMID:
21311689
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.

Menzin J, Boulanger L, Marton J, Guadagno L, Dastani H, Dirani R, Phillips A, Shah H.

Respir Med. 2008 Sep;102(9):1248-56. doi: 10.1016/j.rmed.2008.04.009. Epub 2008 Jul 11.

PMID:
18620852
[PubMed - indexed for MEDLINE]
Free Article
9.

Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.

Bickston SJ, Waters HC, Dabbous O, Tang BI, Rahman M.

J Manag Care Pharm. 2008 May;14(4):352-62.

PMID:
18500913
[PubMed - indexed for MEDLINE]
Free Article
10.

Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.

Delea TE, Hagiwara M, Dalal AA, Stanford RH, Blanchette CM.

Curr Med Res Opin. 2009 Jan;25(1):1-13. doi: 10.1185/03007990802534020 .

PMID:
19210134
[PubMed - indexed for MEDLINE]
11.

Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.

Akazawa M, Biddle AK, Stearns SC.

Clin Ther. 2008;30 Spec No:1003-16. doi: 10.1016/j.clinthera.2008.05.020.

PMID:
18640475
[PubMed - indexed for MEDLINE]
13.

Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population.

Simoni-Wastila L, Yang HW, Blanchette CM, Zhao L, Qian J, Dalal AA.

Curr Med Res Opin. 2009 Nov;25(11):2729-35. doi: 10.1185/03007990903267157.

PMID:
19778165
[PubMed - indexed for MEDLINE]
14.

Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.

Faught RE, Weiner JR, Guérin A, Cunnington MC, Duh MS.

Epilepsia. 2009 Mar;50(3):501-9. doi: 10.1111/j.1528-1167.2008.01794.x. Epub 2008 Oct 3.

PMID:
19183224
[PubMed - indexed for MEDLINE]
15.

Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.

Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J.

Clin Ther. 2009 Nov;31(11):2653-64. doi: 10.1016/j.clinthera.2009.11.032.

PMID:
20110008
[PubMed - indexed for MEDLINE]
16.

Assessing the costs of chronic obstructive pulmonary disease: the state medicaid perspective.

Marton JP, Boulanger L, Friedman M, Dixon D, Wilson J, Menzin J.

Respir Med. 2006 Jun;100(6):996-1005. Epub 2005 Nov 8.

PMID:
16288858
[PubMed - indexed for MEDLINE]
Free Article
17.

Pharmacoeconomic evaluation of COPD.

Hilleman DE, Dewan N, Malesker M, Friedman M.

Chest. 2000 Nov;118(5):1278-85.

PMID:
11083675
[PubMed - indexed for MEDLINE]
18.

Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.

Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, Neumann PJ.

J Manag Care Pharm. 2010 May;16(4):264-75.

PMID:
20433217
[PubMed - indexed for MEDLINE]
Free Article
19.

Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs*.

Delea TE, Stanford RH, Hagiwara M, Stempel DA.

Curr Med Res Opin. 2008 Dec;24(12):3435-42. doi: 10.1185/03007990802557344 .

PMID:
19032125
[PubMed - indexed for MEDLINE]
20.

Cost and utilization of COPD and asthma among insured adults in the US.

Blanchette CM, Broder M, Ory C, Chang E, Akazawa M, Dalal AA.

Curr Med Res Opin. 2009 Jun;25(6):1385-92. doi: 10.1185/03007990902875927.

PMID:
19419342
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk